Epoetin alpha in multiple myeloma: literature review and our own experience

Cover Page

Cite item

Full Text

Abstract

Background. Anemia is the main symptom of multiple myeloma (MM) both at the time of disease onset and during tumor progression. Previously, the main method of anemia treatment was blood transfusion therapy. Currently, blood transfusions are supplemented by erythropoietin (EPO) administration. Safety and effectiveness of the drug have been proven in multiple trials including trials involving oncohematological patients.

Aim. To present the results of using epoetin alpha (Eralfon) in patients with MM complicated by dialysis-dependent myeloma cast nephropathy in real clinical practice; to analyze the literature data on the use of EPO for the treatment of anemia in MM patients.

Materials and methods. A retrospective analysis of a series of clinical observations was carried out: 4 patients with newly diagnosed MM at the ages between 52 and 60 years who underwent treatment at the Department of Hematology and Chemotherapy of Paraproteinemic Hemablastoses with a Bone Marrow and Hematopoietic Stem Cell Transplantation Block. All patients were diagnosed with myeloma cast nephropathy with significantly decreased glomerular filtration rate of 7–15 mL/min requiring renal replacement therapy. At the time of disease diagnosis, median hemoglobin level was 75 g/L, median creatinine level was 517.5 µmole/L. Endogenous EPO level was measured in all patients prior to epoetin alpha prescription: it varied between 2.31 and 149.6 IU/mL. Epoetin alpha (Eralfon) was prescribed at dose 12 000 IU – 0.3 mL subcutaneously 3 times a week. A review of the literature data on the use of EPO in patients with MM was conducted.

Results. All patients at MM onset were dependent on renal replacement therapy and blood transfusion, therefore epoetin alpha was prescribed immediately. In case of renal function recovery and end of dialysis at target hemoglobin levels, administration of the drug was ceased. If dependence on renal replacement therapy persisted, epoetin alpha treatment continued as synthetic function of EPO-producing cells was compromised. In all clinical cases, epoetin alpha therapy was effective.

Conclusion. Clot formation prevention should be kept in mind during epoetin alpha therapy. Decreased requirement for blood transfusions, improved quality of life with favorable safety profile of the drug make epoetin alpha an indispensable part of accompanying therapy in patients with MM and anemia.

About the authors

M. V. Soloveva

National Medical Research Center for Hematology, Ministry of Health of Russia

Author for correspondence.
Email: solomaiia@yandex.ru
ORCID iD: 0000-0003-4142-171X

Maiya Valeryevna Sloloveva

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

M. V. Solovev

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-7944-6202

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

A. A. Startsev

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-6236-7137

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

E. Z. Irugova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-2013-9507

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

N. K. Arutiunian

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-5952-0244

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

A. A. Kraizman

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0003-1934-8800

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

A. V. Abakumova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0003-1035-8762

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

L. P. Mendeleeva

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-4966-8146

4a Noviy Zukovskiy Proezd, Moscow, 125167

Russian Federation

References

  1. Miyake T.K., Kung C.K., Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252(15):5558-64.
  2. Carnot P., Deflandre C. Sur l’activite hemopoietiquedes differents organeau au cours de la regeneration dusang. C R Searces Acad Sci 1906;143:432-5.
  3. Lin F.K., Suggs S., Lin C.H. et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985;82(22):7580-4. doi: 10.1073/pnas.82.22.7580
  4. Jacobs K., Shoemaker C., Rudersdorf R. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806-10. doi: 10.1038/313806a0
  5. Fluck R. Erythropoiesis-stimulating agents in kidney and cardiac disease. Br J Hosp Med (Lond) 2006;67(10):533-7. doi: 10.12968/hmed.2006.67.10.22060
  6. Bunn H.F. Erythropoietin. Cold Spring Harb Perspect Med 2013;3(3):a011619.
  7. Miljus N., Massih B., Weis M.A. et al. Neuroprotection and endocytosis: erythropoietin receptors in insect nervous systems. J Neurochem 2017;141(1):63-74. doi: 10.1111/jnc.13967
  8. Choi D., Schroer S.A., Lu S.Y. et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010;207(13):2831-42. doi: 10.1084/jem.20100665
  9. Nairz M., Schroll A., Moschen A.R. et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity 2011;34(1):61-74. doi: 10.1016/j.immuni.2011.01.002
  10. Liu N.M., Tian J., Wang W.W. et al. Effect of erythropoietin on mesenchymal stem cell differentiation and secretion in vitro in an acute kidney injury microenvironment. Genet Mol Res 2013;12(4):6477-87. doi: 10.4238/2013.February.28.14
  11. Bennis Y., Sarlon-Bartoli G., Guillet B. et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost 2012;10(9):1914-28. doi: 10.1111/j.1538-7836.2012.04835.x
  12. Denisyuk T.A. Recombinant erythropoietin and correction of endotoksin-induced endothelial dysfunction by statin. Kurskiy nauchno-prakticheskiy zhurnal “Chelovek i ego zdorovye” = Kursk Scientific and Practical Bulletin “Man and His Health”. 2016;(2):61-5. (In Russ.). doi: 10.21626/vestnik/2016-2/11.
  13. Xu B., Dong G.H., Liu H. et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci 2005;35(2):161-8.
  14. He H., Qiao X., Wu S. Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy. Exp Ther Med 2013;6(2):567–73. doi: 10.3892/etm.2013.1134
  15. Hooshmandi E., Moosavi M., Katinger H. et al. CEPO (carbamylated erythropoietin)-Fc protects hippocampal cells in culture against beta amyloid-induced apoptosis: considering Akt/ GSK-3β and ERK signaling pathways. Mol Biol Rep 2020;47(3):2097-108. doi: 10.1007/s11033-020-05309-6
  16. Na N., Zhao D., Zhang J. et al. Carbamylated erythropoietin regulates immune responses and promotes long-term kidney allograft survival through activation of PI3K/AKT signaling. Signal Transduct Target Ther 2020;5(1):194. doi: 10.1038/s41392-020-00232-5
  17. Chen J., Yang Z., Zhang X. Carbamylated erythropoietin: a prospective drug candidate for neuroprotection. Biochem Insights 2016;8(Suppl 1):25-9. doi: 10.4137/BCI.S30753
  18. Boesch S., Nachbauer W., Mariotti C. et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord 2014;29(7):935-9. doi: 10.1002/mds.25836
  19. Delyagin V.M., Dzhumagaziev A.A. Erythropoietin: history and prospects of investigation. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal 2013;8(2):18-23. (In Russ.).
  20. German K.R., Juul S.E. Neonatal anemia. Curr Pediatr Rev 2023;19(4):388-94. doi: 10.2174/1573396319666221121140627
  21. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20): 2085-98. doi: 10.1056/NEJMoa065485
  22. Kyle R.A., Gertz M.A., Witzig T.E. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78(1):21-33. doi: 10.4065/78.1.21
  23. Birgegård G., Gascón P., Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 2006;77(5):378-86. doi: 10.1111/j.1600-0609.2006.00739.x
  24. Ludwig H., Rai K., Blade J. et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002;3(3):121-30. doi: 10.1038/sj.thj.6200160
  25. Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708-14. doi: 10.1093/jnci/djj189
  26. Seidenfeld J., Pipe M.J., Bohlius J. et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment [Internet]. Comparative effectiveness review No. 3. Prepared by Blue Cross and Blue Shield Association Evaluation Center Evidence-based Practice Center. Rockville (MD): AHRQ, 2006. Available at: www.effectivehealthcare.arhq.gov/reports/final.cfm.
  27. Ross S.D., Allen I.E., Henry D.H. et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28(6):801-31. doi: 10.1016/j.clinthera.2006.06.003
  28. Aapro M., Coiffier B., Dunst J. et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 2006;95(11):1467-73. doi: 10.1038/sj.bjc.6603481
  29. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373(9674):1532-42. doi: 10.1016/S0140-6736(09)60502-X
  30. Dammacco F., Castoldi G., Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113(1):172-9. doi: 10.1046/j.1365-2141.2001.02715.x
  31. Rosti G., Petrini M., Bosi A. et al. Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. Ther Adv Med Oncol 2017;9(1):22-32. doi: 10.1177/1758834016670554
  32. Aapro M., Moebus V., Nitz U. et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Ann Oncol 2015;26(4):688-95. doi: 10.1093/annonc/mdu579
  33. Oster H.S., Gvili Perelman M., Kolomansky A. et al. Erythropoietin treatment is associated with decreased blood glucose levels in hematologic patients. Acta Haematol 2021;144(3):252-8. doi: 10.1159/000507974
  34. Losem C., Koenigsmann M., Rudolph C. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Onco Targets Ther 2017;10:1295-305. doi: 10.2147/OTT.S122427
  35. Ludwig H., Fritz E., Kotzmann H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322(24):1693-9. doi: 10.1056/NEJM199006143222402
  36. Garton J.P., Gertz M.A., Witzig T.E. et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995;155(19):206-74.
  37. Dammacco F., Silvestris F., Castoldi G.L. et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998;28(2):127-34. doi: 10.1007/s005990050032
  38. Barlogie B., Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993;11(2):88-94. doi: 10.1002/stem.5530110203
  39. Marsh W.A., Rascati K.L. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clin Ther 1999;21(9):1443-55; discussion 1427-8. doi: 10.1016/s0149-2918(00)80003-x
  40. Glaspy J., Demetri G., Cremieux P. Does baseline endogenous erythropoietin level impact hemoglobin (Hb) response to rHuEPO in cancer patients? Blood 1999;94(Suppl 1; Part 2):15b(abstract).
  41. Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkinʼs lymphoma: dose finding and identification of predictors of response. Blood 1995;86(12):4446-53.
  42. Osterborg A., Boogaerts M.A., Cimino R. et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkinʼs lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkinʼs Lymphoma. Blood 1996;87(7):2675-82.
  43. Silvestris F., Romito A., Fanelli P. et al. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995;70(6):313-8. doi: 10.1007/BF01696618
  44. Solovyev M.V., Solovyeva M.V., Mendeleeva L.P. Supportive therapy in multiple myeloma: practical recommendations. Klinicheskaya onkogematologiya = Clinical oncohematology 2023;16(4):426-48. (In Russ.). doi: 10.21320/2500-2139-2023-16-4-426-448.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.